Vivozon Pharmaceutical Valuation

Is A082800 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A082800 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A082800's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A082800's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A082800?

Key metric: As A082800 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A082800. This is calculated by dividing A082800's market cap by their current revenue.
What is A082800's PS Ratio?
PS Ratio	3.4x
Sales	₩81.52b
Market Cap	₩276.96b

A082800 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.8x
Enterprise Value/EBITDA	39.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A082800's PS Ratio compare to its peers?

The above table shows the PS ratio for A082800 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.7x
A084850 ITM Semiconductor	0.5x	13.8%	₩299.6b
A101160 Worldex Industry & Trading	1x	n/a	₩280.5b
A123860 Anapass	2.1x	59.5%	₩246.7b
A218410 RFHIC	3.2x	25.2%	₩346.8b
A082800 Vivozon Pharmaceutical	3.4x	n/a	₩277.0b

Price-To-Sales vs Peers: A082800 is expensive based on its Price-To-Sales Ratio (3.4x) compared to the peer average (1.7x).

Price to Sales Ratio vs Industry

How does A082800's PS Ratio compare vs other companies in the KR Semiconductor Industry?

10 Companies	Price / Sales	Estimated Growth	Market Cap
A082850 Wooree BioLtd	0.1x	n/a	US$112.22m
A033160 MK Electron	0.1x	n/a	US$103.96m
A004710 Hansol Technics	0.1x	n/a	US$89.53m
A077500 Uniquest	0.2x	n/a	US$78.10m

10 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A082800 is expensive based on its Price-To-Sales Ratio (3.4x) compared to the KR Semiconductor industry average (1.2x).

Price to Sales Ratio vs Fair Ratio

What is A082800's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A082800 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A082800's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Advanced Process Systems

₩243.6b

Develops and sells semiconductors and display manufacturing equipment primarily in South Korea, China, and Vietnam.

A265520

₩16,220.00

2.6%

-20.5%

HAESUNG DS

₩380.0b

Manufactures and sells semiconductor components in South Korea and internationally.

A195870

₩22,350.00

9.0%

-56.2%

HANA Micron

₩587.8b

Provides semiconductor back-end process packaging solutions in South Korea.

A067310

₩9,750.00

5.5%

-61.0%